Focal adhesion kinase as potential target for cancer therapy

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 973-979

  Hao, Huifang ^a   Naomoto, Yoshio ^a   Bao, Xiaohong ^a   Watanabe, Nobuyuki ^a   Sakurama, Kazufumi ^a   Noma, Kazuhiro ^a   Motoki, Takayuki ^a   Tomono, Yasuko ^b   Fukazawa, Takuya ^a   Shirakawa, Yasuhiro ^a   Yamatsuji, Tomoki ^a   Matsuoka, Junji ^a   Wang, Z G ^c   Takaoka, Munenori ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Shigei Medical Research Institute   (Japan)

^c INNER MONGOLIA UNIVERSITY   (China)

Author keywords

FAK inhibitor; FAK related non kinase; FERM; Focal adhesion kinase

Indexed keywords

ENZYME INHIBITOR; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; INTEGRIN; MESSENGER RNA; NVP 226; PF 562,271; PF 562271; PF 573,228; PF 573228; PROTEIN FERM; PROTEIN P53; TAE 226; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CANCER INHIBITION; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL ADHESION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; DRUG DESIGN; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; GENE OVEREXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; NEOPLASMS;

EID: 70449347073     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000524     Document Type: Review

References (103)

1. FAK, a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Cell Biol 89: 5192-5196, 1992.
2. Hanks SK, Calalb MB, Harper MC and Patel SK: Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Cell Biol 89: 8487-8491, 1992.
3. Fiedorek FT Jr and Kay ES: Mapping of the focal adhesion kinase (Fak) gene to mouse chromosome 15 and human chromosome 8. Mamm Genome 6: 123-126, 1995.
4. Schaller MD: Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 1540: 1-21, 2001.
5. Sasaki H, Nagura K, Ishino M, Tobioka H, Kotanik K and Sasaki T: Cloning and kinase characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion subfamily. J Biol Chem 270: 21206-21219, 1995.
6. Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B and Schlessinger J: Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature 376: 737-745, 1995.
7. Avraham S, London R, Fu Y, et al: Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem 270: 27742-27751, 1995.
8. Yu H, Li X, Marchetto GS, Dy R, Hunter D, Calvo B, Dawson TL, Wilm M, Anderegg RJ, Graves LM and Earp HS: Activation of a novel calcium-dependent protein-tyrosine kinase. Correlation with c-Jun N-terminal kinase but not mitogen-activated protein kinase activation. J Biol Chem 271: 29993-29998, 1996.
9. Zachary I: Focal adhesion kinase. Int J Biochem Cell Biol 29: 929-934, 1997.
10. Parsons JT: Focal adhesion kinase: the first ten years. J Cell Sci 116: 1409-1416, 2003.
11. Calalb MB, Polte TR and Hanks SK: Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinase. Mol Cell Biol 15: 954-963, 1995.
12. Schlaepfer DD and Hunter T: Signal transduction from the extracellular matrix - a role for the focal adhesion-tyrosine kinase FAK. Cell Struct Funct 21: 445-450, 1996.
13. Martin KH, Boerner SA and Parsons JT: Regulation of focal adhesion targeting and inhibitory functions of the FAK related protein FRNKN using a novel estrogen receptor 'switch'. Cell Motil Cytoskeleton 51: 76-88, 2002.
14. Hildebrand JD, Schaller MD and Parsons JT: Identification of sequences required for the efficient loclization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions. J Cell Biol 123: 993-1005, 1993.
15. Arold ST, Hoellerer MK and Noble ME: The structural basis of localization and signaling by the focal adhesion targeting domain. Structure 10: 319-327, 2002.
16. Hayashi I, Vuori K and Liddington RC: The focal adhesion targeting (FAT) region of focal adhesion kinase is a four-helix bundle that binds paxillin. Nat Struct Biol 9: 101-106, 2002.
17. Liu G, Guibao CD and Zheng J: Structural insight into the mechanisms of targeting and signaling of focal adhesion kinase. Mol Cell Biol 22: 2751-2760, 2002.
18. Brown MC, Perrotta JA and Turner CE: Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding. J Cell Biol 135: 1109-1123, 1996.
19. Bertolucci CM, Guibao CD and Zheng J: Structural features of the focal adhesion kinase-paxillin complex give insight into the dynamics of focal adhesion assembly. Protein Sci 14: 644-652, 2005.
20. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD and Guan JL: Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem 270: 16995-16999, 1995.
21. Schaller MD, Borgman CA and Parsons JT: Autonomous expression of a non-catalytic domain of the focal adhesion-associated protein tyrosine kinase pp125FAK. Mol Cell Biol 13: 785-791, 1993.
22. Nolan K, Lacoste J and Parsons JT: Regulated expression of focal adhesion kinase-related non-kinase, the autonomously expressed c-terminal domain of focal adhesion kinase. Mol Cell 19: 6120-6129, 1999.
23. FAK. Nature 380: 538-540, 1996.
24. Taylor JM, Rovin JD and Parsons JT: A Role for focal adhesion kinase in phenylephrine-induced hypertrophy of rat ventricular cardiomyocytes. J Biol Chem 275: 19250-19257, 2000.
25. Taylor JM, Mack CP, Nolan K, Regan CP, Owens GK and Parsons JT: Selective expression of an endogenous inhibitor of FAK regulates proliferation and migration of vascular smooth muscle cells. Mol Cell Biol 21: 1565-1572, 2001.
26. Hauck CR, Sieg DJ, Hsia DA, Loftus JC, Gaarde WA, Monia BP and Schlaepfer DD: Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res 61: 7079-7090, 2001.
27. Richardson A, Shannon JD, Adams RB, Schaller MD and Parsons: Identification of integrin-stimulated sites of serine phosphorylation in FRNK, the separately expressed C-terminal domain of focal adhesion kinase: a potential role for protein kinase A. Biochem J 324: 141-149, 1997.
28. Chishti AH, Kim AC, Marfatia SM, et al: The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci 23: 281-282, 1998.
29. Girault JA, Labesse G, Mornon JP and C: Theallebaut I: N-termini of FAK and JAKs contain divergent band 4.1 domains. Trends Biochem Sci 24: 54-57, 1999.
30. Cooper LA, Shen TL and Guan JL: Regulation of focal adhesion kinase by its amino-terminal domain through an autoinhibitory interaction. Mol Cell Biol 23: 8030-8041, 2003.
31. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH and Schlaepfer DD: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2: 249-256, 2000.
32. Van Nimwegen MJ and van de Water B: Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 73: 597-609, 2007.
33. Ceccarelli DF, Song HK, Poy F, Schaller MD and Eck MJ: Crystal structure of the FERM domain of focal adhesion kinase. J Biol Chem 281: 252-259, 2006.
34. Chan PY, Kanner SB, Whitney G and Aruffo A: A transmembrane-anchored chimeric focal adhesion kinase is constitutively activated and phosphorylated at tyrosine residues identical to pp125FAK. J Biol Chem 269: 20567-20574, 1994.
35. Schlaepfer DD and Hunter T: Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Mol Cell Biol 16: 5623-5633, 1996.
36. Lietha D, Cai X, Ceccarelli DF, Li Y, Schaller MD and Eck MJ: Structural basis for the autoinhibition of focal adhesion kinase. Cell 129: 1177-1187, 2007.
37. Golubovskaya VM, Finch R and Cance WG: Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. Biol Chem 280: 25008-25021, 2005.
38. Golubovskaya VM, Finch R, Kweh F, Massoll NA, Campbell-Thompson M, Wallace MR and Cance WG: p53 regulates FAK expression in human tumor cells. Mol Carcinog 47: 373-382, 2008.
39. Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, Larocque N, Fisher SJ, Schlaepfer DD and Ilic D: Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 29: 9-22, 2008.
40. Golubovskaya VM, Kweh FA and Cance WG: Focal adhesion kinase and cancer. Histol Histopathol 24: 503-510, 2009.
41. Assoian RK and Klein EA: Growth control by intracellular tension and extracellular stiffness trends. Cell Biol 18: 347-352, 2008.
42. Cukierman E, Pankov R, Stevens DR and Yamada KM: Taking cell-matrix adhesions to the third dimension. Science 294: 1708-1712, 2001.
43. Hehlgans S, Haase M and Cordes N: Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775: 163-180, 2007.
44. Tachibana K, Sato T, D'Avirro N and Morimoto C: Direct association of pp125FAK with paxillin the focal adhesion-targeting mechanism of pp125FAK. J Exp Med 182: 1089-1099, 1995.
45. Kornberg L, Earp HS, Parsons JT, Schaller M and Juliano RL: Cell adhesion or integrin clustering increase phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem 267: 23439-23442, 1992.
46. Mitra SK and Schlaepfer DD: Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18: 516-523, 2006.
47. Schlaepfer DD, Mitra SK and Ilic D: Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692: 77-102, 2004.
48. Playford MP and Schaller MD: The interplay between Src and integrins in normal and tumor biology. Oncogene 23: 7928-7946, 2004.
49. Cho SY and Klemke RL: Extracellular-regulated kinase activation and Cas/ Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J Cell Biol 149: 223-236, 2000.
50. Klemke RL, Leng J, Molander R, Brooks PC, Vuori K and Cheresh DA: CAS/ Crk coupling serves as a 'molecular switch' for induction of cell migration. J Cell Biol 140: 961-972, 1998.
51. Dolfi F, Garcia-Guzman M, Ojaniemi M, Nakamura H, Matsuda M and Vuori K: The adaptor protein Crk connects multiple cellular stimuli to the JNK signaling pathway. Proc Natl Acad Sci USA 95: 15394-15399, 1998.
52. Cox BD, Natarajan M, Stettner MR and Gladson CL: New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem 99: 35-52, 2006.
53. Sonoda Y, Watanabe S, Matsumoto Y, Aizu-Yokota E and Kasahara T: FAK is the upstream signal protein of the phosphatidylinositol 3-Kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line. J Biol Chem 274: 10566-10570, 1999.
54. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
55. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Scjlaepfer DD and Damsky CH: Matrix survival signaling from fibronectin via focal adhesion kinase to C-Jun Nh2-terminal kinase. J Cell Biol 149: 741-754, 2000.
56. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N and TP53-CRC Collaborative Study Group: The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23: 7518-7528, 2005.
57. Vousden KH: Switching from life to death: the Miz-ing link between Myc and p53. Cancer Cell 2: 351-352, 2002.
58. Iwakuma T and Lozano G: MDM2: an introduction. Mol Cancer Res 1: 993-1000, 2003.
59. Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S and Damsky CH: Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. J Cell Biol 143: 547-560, 1998.
60. Zhang Y, Lu H, Dazin P and Kapila Y: Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated Anoikis: fibronectin and integrin alphav mediate survival signals through focal adhesion kinase. J Biol Chem 279: 48342-48349, 2004.
61. Livasy CA, Moore D, Cance WG and Lininger RA: Focal adhesion kinase overexpression in endometrial neoplasia. Appl Immunohistochem Mol Morphol 12: 342-345, 2004.
62. Lewis JM, Truong TN and Schwartz MA: Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proc Natl Acad Sci USA 99: 3627-3632, 2002.
63. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG and Frame MC: The role of focal-adhesion kinase in cancer, a new therapeutic opportunity. Nat Rev Cancer 5: 505-515, 2005.
64. Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK and Kasahara T: Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhbitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 275: 16309-16315, 2000.
65. Draetta GF: Mammalian G1 cyclins. Curr Opin Cell Biol 6: 842-846, 1994.
66. Zhao J, Pestell R and Guan JL: Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression. Mol Biol Cell 12: 4066-4077, 2001.
67. Yamamoto D, Sonoda Y, Hasegawa M, Funakoshi-Tago M, Aizu-Yokota E and Kasahara T: FAK overexpression upregulates cyclin D3 and enhances cell proliferation via the PKC and PI3-kinase-Akt pathways. Cell Signal 15: 575-583, 2003.
68. Burridge K, Turner CE and Romer LH: Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol 119: 893-903, 1992.
69. Cary LA, Chang JF and Guan JL: Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci 109: 1787-1794, 1996.
70. Cas as a mediator of focal adhesion kinase-promoted cell migration. J Cell Biol 140: 211-221, 1998.
71. Reiske HR, Kao SC, Cary LA, Guan JL, Lai JF and Chen HC: Requirement of phosphatidylinositol 3-Kinase in focal adhesion kinase-promoted cell migration. J Biol Chem 274: 12361-12366, 1999.
72. Serrels B, Serrels A, Brunton VG, Holt M, Mclean GW, Gray CH, Jones GE and Frame MC: Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex. Nat Cell Biol 9: 1046-1056, 2007.
73. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M and Yamamoto T: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377: 539-544, 1995.
74. Owen JD, Ruest PJ, Fry DW and Hanks SK: Induced focal adhesion kinase (FAK) expression in FAK null cells enhances cell spreading and migration requiring Both auto- and activation loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of Pyk2. Mol Cell Biol 19: 4806-4818, 1999.
75. Sieg DJ, Hauck CR and Schlaepfer DD: Required role of focal adhesion kinase (FAK) for intergrin stimulated cell migration. J Cell Sci 112: 2677-2691, 1999.
76. Watanabe N, Takaoka M, Sakurama K, et al: Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin Cancer Res 14: 4631-4639, 2008.
77. Weiner TM, Liu ET, Craven RJ and Cance WG: Expression of focal adhesion kinase gene and invasive cancer. Lancet 342: 1024-1025, 1993.
78. Lightfoot HM Jr, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L, Craven RJ and Cance WG: Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat 88: 109-116, 2004.
79. Lark AL, Livasy CA, Calvo B, Caskey L, Moore DT, Yang X and Cance WG: Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases. Clin Cancer Res 9: 215-222, 2003.
80. Zagzag D, Friedlander DR, Margolis B, Grumet M, Semenza GL, Zhong H, Simons JW, Holash J, Wiegand SJ and Yancopoulos GD: Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg 33: 49-55, 2000.
81. Haskell H, Natarajan M, Hecker TP, Ding Q, Stewart J Jr, Grammer JR and Gladson CL: Focal adhesion kinase is expressed in the angiogenic bloodvessels of malignant astrocytic tumors in vivo and promotes capillary tubeformation of brain microvascular endothelial cells. Clin Cancer Res 9: 2157-2165, 2003.
82. Xu LH, Owens LV, Sturge GC, Yang X, Liu ET, Craven RJ and Cance WG: Attenuation of the expression of the focal adhesion induces apoptosis in tumor cells. Cell Growth Differ 7: 413-418, 1996.
83. Frisch SM, Vuori K, Ruoslahti E and Chan-Hui PY: Control of adhesion-dependent cell by focal adhesion kinase. J Cell Biol 134: 793-799, 1996.
84. Crouch DH, Fincham VJ and Frame MC: Targeted proteolusis of the focal adhesion kinase pp125FAK during c-MYC-induced apoptosis is suppressed by intergrin signalling. Oncogene 12: 2689-2696, 1996.
85. Wen LP, Fahrni JA, Troie S, Guan JL, Orth K and Rosen GD: Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem 272: 26056-26061, 1997.
86. Lipinski CA, Tran NL, Bay C, Kloss J, McDonough WS, Beaudry C, Berens ME and Loftus JC: Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. Mol Cancer Res 1: 323-332, 2003.
87. Lipinski CA, Tran NL, Menashi E, Rohl C, Kloss J, Bay RC, Berens ME and Loftus JC: The tyrosine kinase PYK2 promotes migration and invasion of glioma cells. Neoplasia 7: 435-445, 2005.
88. Wu ZM, Yuan XH, Jiang PC, Li ZQ and Wu T: Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells. J Neurooncol 77: 117-123, 2006.
89. Richardson A, Malik RK, Hildebrand JD and Parsons JT: Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by co-expression of Src or catalytically inactive FAK: a role for paxillin tyrosine phosphorylation. Mol Cell Biol 17: 6906-6914, 1997.
90. Xu LH, Yang X, Craven RJ and Cance WG: The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ 9: 999-1005, 1998.
91. Xu LH, Yang X, Bradham CA, Brenner DA, Baldwin AS Jr, Craven RJ and Cance WG: The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. J Biol Chem 275: 30597-305604, 2000.
92. Golubovskaya V, Beviglia L, Xu LH, Earp HS III, Craven R and Cance W: Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 277: 38978-38987, 2002.
93. Xiong W and Parsons JT: Induction of apoptosis after expression of PYK2, a tyrosine kinase structurally related to focal adhesion kinase. J Cell Biol 139: 529-539, 1997.
94. McLean GW, Komiyama NH, Serrels B, et al: Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev 18: 2998-3003, 2004.
95. Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, Flavell RA, Gu H and Guan JL: Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 169: 941-952, 2005.
96. Beggs HE, Schahin-Reed D, Zang K, Goebbels S, Nave KA, Gorski J, Jones KR, Sretavan D and Reichardt LF: FAK deficiency in cells contributing to the basal lamina results in cortical abnormalities resembling congenital muscular dystrophies. Neuron 40: 501-514, 2003.
97. Slack-Davis JK, Martin KH, Tilghman RW, et al: Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282: 14845-14852, 2007.
98. Shi Q, Hjelmeland AB, Keir ST, et al: A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog 46: 488-496, 2007.
99. Liu TJ, LaFortune T, Honda T, et al: Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 6: 1357-1367, 2007.
100. Golubovskaya VM, Virnig C and Cance WG: TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR. Mol Carcinog 47: 222-234,2008.
101. Halder J, Lin YG, Merritt WM, et al: Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67: 10976-10983, 2007.
102. Roberts WG, Ung E, Whalen P, et al: Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res 68: 1935-1944, 2008.
103. Gabarra-Niecko V, Schaller MD and Dunty JM: FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 22: 359-374, 2003.